ClinicalTrials.gg

Program

vustanaciclib

Also written as “RGT-419B”, “GDC-4198” and “RGT-419B in combination with hormonal therapy”.

Its studies are mostly in Breast Neoplasms, led by 2 companies.

Furthest: phase 2, since Feb 24, 20223 company-led studies, 3 open or runningNext primary completion: Dec 30, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Regor Pharmaceuticals22 open or runningphase 1since Feb 24, 2022Feb 24, 2022Dec 30, 2026phase 1 · NCT06299124
Hoffmann-La Roche11 open or runningphase 2since Jul 31, 2025Jul 31, 2025Aug 31, 2028phase 2 · NCT07100106
  • Named in Hoffmann-La Roche’s own pipeline as RG6794 vustanaciclib, phase 2, as of Oct 22, 2026 (source).

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 24, 2022First study: phase 1 study in Breast NeoplasmsNew to Regor PharmaceuticalsRegor Pharmaceuticals · NCT05304962 · 64 planned · United States
  2. Mar 1, 2024Phase 1 study in Breast NeoplasmsRegor Pharmaceuticals · NCT06299124 · 40 enrolled · China
  3. Jul 31, 2025Hoffmann-La Roche's first study: phase 2 study in Breast NeoplasmsNew to Hoffmann-La RocheHoffmann-La Roche · NCT07100106 · 285 planned · United States, Australia, Brazil and more

Ahead

  1. Dec 30, 2026Primary completion: phase 1 study in Breast NeoplasmsRegor Pharmaceuticals · NCT06299124
  2. Dec 30, 2026Primary completion: phase 1 study in Breast NeoplasmsRegor Pharmaceuticals · NCT05304962
  3. Aug 31, 2028Primary completion: phase 2 study in Breast NeoplasmsHoffmann-La Roche · NCT07100106

TargetBeta

“An orally bioavailable third-generation inhibitor of cyclin-dependent kinase (CDK) types 2 (CDK2), 4 (CDK4) and 6 (CDK6), with potential antineoplastic activity. Upon oral administration, vustanaciclib selectively targets and inhibits CDK2, CDK4 and CDK6, which inhibits the phosphorylation of ret…”NCIt, read by Claude
“An orally bioavailable third-generation inhibitor of cyclin-dependent kinase (CDK) types 2 (CDK2), 4 (CDK4) and 6 (CDK6), ”NCIt, by rule

Other programs on the same three targets

ProgramCompanyFurthest phaseStudies
culmerciclibSino Biopharmaceuticalphase 311

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07100106Breast Neoplasms · United States, Australia, Brazil and more2RecruitingHoffmann-La RocheAug 31, 2028285
NCT06299124Breast Neoplasms · China1Active, not recruitingRegor PharmaceuticalsDec 30, 202640
NCT05304962Breast Neoplasms · United States1RecruitingRegor PharmaceuticalsDec 30, 202664

How it is read

Names in the registry

  • “RGT-419B”, 2 entries
  • “GDC-4198”, 1 entry
  • “RGT-419B in combination with hormonal therapy”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.